Seeking Alpha

Seeking Alpha Portfolio App for iPad

2,618 people get PPHM articles and Market Currents by email alert.

Get email alerts on PPHM »

PPHM

Peregrine Pharmaceuticals Inc.

5/18/2013, 1:28 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Monday, April 29, 9:27 AM Peregrine Pharmaceuticals (PPHM) says it has completed enrollment in a Phase I trial for bavituximab to evaluate the safety, feasibility, and tolerability of the drug in combination with the chemotherapeutic agent paclitaxel for the treatment of breast cancer. Shares +7% premarket. (PR) Comment! [Healthcare, On the Move]
Monday, April 29, 9:15 AM Premarket gainers: SINA +22%. CPTS +20%. PPHM +8%. NIHD +8%. THC +7%. PBR +6%. HCA +9%. HMA +5%. MCO +5%. RDN +5%.
Losers: NTE -27%. GORO -9%. NBG -8%. RVLT -5%. Comment! [On the Move]
Wednesday, April 10, 9:10 AM Premarket gainers: ADTN +8%. PPHM +6%. NJ +6%.
Losers: TITN -18%. HMA -14%. SGYP -13%. RLGY -6%. GRA -5%. Comment! [On the Move]
Wednesday, April 10, 9:01 AM Peregrine Pharmaceuticals (PPHM +6%) presents pre-clinical data at the annual meeting of the American Association for Cancer Research showing the potential of the company's Bavituximab drug for fighting lung cancer, and of other molecules that the firm's developing. Peregrine intends to start Phase III trials of Bavituximab later this year. (PR) Comment! [Healthcare]
Wednesday, March 20, 12:45 PM Midday top 10 gainers: OMPI +28%. AFFY +18%. MTSL +13%. NPD +12%. CHYR + 12%. GEVO +12%. WSM +11%. BIOF +10%. AIR +9%. PPHM +8%.
Midday top 10 losers: ATOS -18%. LIVE -15%. MXWL -15%. CHKR -14%. ECT -12%. CIG -13%. SGOC -12%. FFEX -11%. ABCD -11%. OTIV -9%. Comment! [On the Move]
Wednesday, March 13, 9:10 AM Premarket gainers: BGMD +15%. SUMR +10%. PPHM +5%.
Losers: SPPI -36%. VELT -32%. ASMI -13%. EXPR -13%. TEU -10%. DOLE -7%. WFR -6%. Comment! [On the Move]
Tuesday, March 12, 4:18 PM More on Peregrine Pharmaceuticals (PPHM): Q3 beats on all counts as total revenue nearly doubles. The company cites greater contract manufacturing revenue generated by Avid Bioservices, it's wholly-owned contract manufacturing subsidiary, which generated contract manufacturing revenue of $6.9M for the third quarter of FY 2013, compared to $3.2M for the prior year. For the remainder of FY13, it expects contract manufacturing revenue to be at least $20M. Shares +7.6% AH. Comment! [Healthcare, Earnings, On the Move]
Tuesday, March 12, 4:02 PM Peregrine Pharmaceuticals (PPHM): FQ3 EPS of -$0.04 beats by $0.03. Revenue of $7.03M beats by $3.13M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, March 12, 12:10 AM Notable earnings after Tuesday’s close: DOLE, GERN, HRZN, IRET, KTOS, PPHM, VELT Comment! [Earnings]
Monday, March 11, 5:35 PM Notable earnings after Tuesday’s close: DOLE, GERN, HRZN, IRET, KTOS, PPHM, VELT 2 Comments [Earnings]
Friday, March 8, 12:13 PM Shares of Peregrine Pharmaceuticals (PPHM +15%) are surging on no specific news today. Piper initiated the shares with an Overweight earlier this week - which gave the stock a +9% pop - citing optimism over its two novel cancer drug candidates, bavituximab and Cotara. Further data on overall survival rates for bavituximab are expected to be presented at an upcoming scientific meeting later this year. 2 Comments [Healthcare, On the Move]
Wednesday, March 6, 10:50 AM Peregrine Pharmaceuticals (PPHM +5.4%) gains this morning after Piper Jaffray initiated the shares with an Overweight rating and $2.50 price target. Piper says PPHM is advancing two cancer drug candidates that, combined with its hybrid business model, present an attractive risk-reward opportunity. Additionally, the negative press over its lead drug candidate bavituximab has created a potential entry point to pick up the shares at a discount. Comment! [Healthcare, On the Move]
Wednesday, March 6, 9:10 AM Premarket gainers: PRAN +13%. PBR +12%. CYTX +9%. PPHM +8%. GEVO +8%. MTG +8%. TSL +8%. HNR +7%. BIG +7%.PBR.A +6%. PAY +5%. WPRT +5%.
Losers: AVAV -25%. TFM -11%. AEO -9%. SOHU -8%. QIHU -5%. NBG -5%. Comment! [On the Move]
Wednesday, February 27, 11:12 AM Peregrine Pharmaceuticals (PPHM +8.7%) regains some yesterday's decline after the company was featured in a pessimistic article in Seeking Alpha. The stock actually began its fall on Monday, but was exacerbated yesterday by the SA piece by contributor Robert Schwartz, who noted that PPHM's lead drug candidate, bavituximab, has had twelve Phase-I/-II studies and treated 613 cancer patients but has yet to observe a statistically significant improvement over a contemporary standard-of-care. Schwartz thinks its time to throw in the towel. 5 Comments [Healthcare, On the Move]
Tuesday, February 19, 10:51 AM For a second session, Peregrine Pharmaceuticals (PPHM -3.8%) trades up in the premarket only to give back the early gains plus more, as the company announces encouraging but not stellar results in its Phase II clinical update of bavituximab for the treatment of stage IV pancreatic cancer. 3 Comments [Healthcare, On the Move]
Wednesday, February 13, 12:35 PM Shares of Peregrine Pharmaceuticals (PPHM -2%) take a wild swing lower after opening solidly in the green this morning on the back of news that its bavituximab treatment performed well in Phase II trials. Comment! [Healthcare, On the Move]